Adial Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition
Adial Pharmaceuticals, Inc. (ADIL) reported APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition of $199.38 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition · last filed 2025-03-04
- Adial Pharmaceuticals, Inc. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2024 was $199.38K, a 61.19% decline from fiscal 2023.
- Adial Pharmaceuticals, Inc. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2023 was $513.69K.
| Period end | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 12 month |
|---|---|
| 2024-12-31 | $199.38K 10-K · filed 2025-03-04 |
| 2023-12-31 | $513.69K 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |